Aine Miller - 06 Feb 2024 Form 3 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role: SVP, Dev & Head of IRE Office
Signature: /s/ Brett A. Grimaud, Attorney-in-Fact
Issuer symbol: TBPH
Transactions as of: 06 Feb 2024
Net transactions value: $0
Form type: 3
Filing time: 16 Feb 2024, 20:12:31 UTC
Next filing: 22 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	TBPH	Ordinary Shares						145,316	06 Feb 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TBPH	Share Option (Right to Buy)							06 Feb 2024	Ordinary Shares	37,500	$25.42	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares subject to option vesting and became exercisable on March 2, 2021, then 1/48th of the shares subject to the option vest and became exercisable each month thereafter. The Option shall be fully vested and exercisable on March 2, 2024 provided optionee has remained in continuous service through such date.